BS_CTR5X93B
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 37.417871222076215
- age_years
- 5.255
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YVMEEBKC | pilocytic astrocytoma | — | 0.907 |
| 2 | BS_JMHG7GCN | pilocytic astrocytoma | — | 0.880 |
| 3 | BS_4HQ3T2NC | pilocytic astrocytoma | — | 0.880 |
| 4 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.880 |
| 5 | SRR17866835 | — | — | 0.879 |
| 6 | MDT-AP-3274 | Med | Medulloblastoma | 0.878 |
| 7 | BS_H8A9PSYA | pilocytic astrocytoma | — | 0.875 |
| 8 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.871 |
| 9 | BS_42DY6WS7 | pilocytic astrocytoma | — | 0.864 |
| 10 | TCGA-A7-A0CG-01A-12R-A056-07 | — | A | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.458 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.427 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.386 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.382 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.335 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.326 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.311 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.285 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.268 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.266 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.259 | Inavolisib | — uncovered |
| COMPLEMENT | 0.247 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.237 | Inavolisib | — uncovered |
| COAGULATION | 0.233 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.231 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.183 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYOGENESIS | 0.163 | Inavolisib | — uncovered |